AUTL - Autolus gains on Phase 2 data presentation on leukemia therapy

2023-06-02 07:51:13 ET

Autolus Therapeutics ( NASDAQ: AUTL ) added ~7% pre-market Friday after announcing Phase 2 data for its CAR T cell therapy obe-cel (AUTO1) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

As previously disclosed, the company said that obe-cel reached the primary endpoint in the pivotal FELIX study for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

Supporting its claim, the company said that in a group of 94 patients who received obe-cel, 76% achieved complete response (CR) or CR with incomplete hematological recovery.

Meanwhile, at 9.5 months of median follow-up, 61% of responders showed ongoing remission without new anti-cancer drugs.

In terms of safety, 3% (3/94) and 7% (7/94) patients experienced Grade ?3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively.

Autolus ( AUTL ) is planning to submit a biologics license application for obe-cel towards the end of the year.

More on Autolus

• Autolus Therapeutics finance chief steps down
• Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data

For further details see: